Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...
TMO heads into Q4 earnings with Specialty Diagnostics growth, fresh FDA approvals and launches that could lift results on Jan. 29.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果